share_log
Reuters ·  Apr 8 07:00
Johnson & Johnson Highlights New Data That Showcase the Strength of Nipocalimab, Demonstrating Long-Term Sustained Disease Control in Adults Living With Generalized Myasthenia Gravis (Gmg)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 366

Recommended

Write a comment